SP 600125 |
Catalog No.GC15344 |
SP 600125 is an orally active, reversible, selective, ATP-competitive JNK inhibitor with IC50 of 40, 40, and 90 nM for JNK1, JNK2, and JNK3, respectively. SP 600125 is commonly used in the research of ovarian cancer, tumors, Parkinson's disease (PD), breast cancer, and asthma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 129-56-6
Sample solution is provided at 25 µL, 10mM.
SP 600125 is an orally active, reversible, selective, ATP-competitive JNK inhibitor with IC50 of 40, 40, and 90 nM for JNK1, JNK2, and JNK3, respectively. SP 600125 is commonly used in the research of ovarian cancer, tumors, Parkinson's disease (PD), breast cancer, and asthma[1,2].
SP 600125 (10-20 μM; 24 h) reduces PMA-dependent MMP-9 secretion and inhibits c-Jun phosphorylation, and also inhibits PMA-stimulated MMP-9 promoter-driven luciferase reporter gene activity[1].SP 600125 inhibits c-Jun phosphorylation with an IC50 of 5-10 μM. SP 600125(5-10 μM,24h) also inhibits LPS-induced increase COX-2 protein levels and PGE2 production[3].
SP 600125 (10/30/50 mg/kg/day; ip) inhibits MPTP-induced JNK activation and c-Jun phosphorylation in the substantia nigra obturata (SNc) and prevents the decrease in dopamine concentration in the striatum and alleviates behavioral impairment in MPTP-treated mice[2]. SP 600125(30mg/kg/day) can significantly reduce the expression of inflammatory cells in the bronchi and lungs under OVA stimulation[4].
References:
[1]. Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta. 2002 May 8;1589(3):311-6.
[2]. Wang W, Shi L, Xie Y, Ma C, Li W, Su X, Huang S, Chen R, Zhu Z, Mao Z, Han Y, Li M. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res. 2004 Feb;48(2):195-202.
[3]. Nieminen R, Lahti A, Jalonen U, Kankaanranta H, Moilanen E. JNK inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages. Int Immunopharmacol. 2006 Jun;6(6):987-96.
[4].Wu HM, Fang L, Shen QY, Liu RY. SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model. Mol Immunol. 2015 Oct;67(2 Pt B):311-6.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *